D’Amico Risk Classification for Prostate Cancer

Formula

Pearls / Pitfalls

Developed in 1998, estimates risk of prostate cancer recurrence (low, medium or high) from PSA level, Gleason Score , and tumor stage. May be less accurate in men with multiple risk factors.

Advice

With changing treatment patterns, there is a large variation on how to treat different risk groups. Low risk patients seem to do well with many treatment modalities. Intermediate risk patients are a very variable group, where further understanding of risk of cancer “beyond the gland” may be necessary to guide treatment. High risk groups often do best with a multimodal treatment approach.

More Information

Low risk: Gleason Score <6 and PSA <10 ng/ml and Clinical stage T1c or T2a Intermediate risk: Gleason Score of 7 or PSA of 10-20 ng/ml Clinical stage T2b High risk: Gleason Score >8 or PSA >20 ng/ml or Clinical stage T2c or T3